Nov 6 (Reuters) - Novavax ( NVAX ) beat Wall Street
expectations for third-quarter revenue on Thursday, helped by
milestone payments tied to its COVID-19 vaccine partnerships.
The biotech firm reported total revenue of $70.4 million,
compared with analysts' average estimate of $42.13 million,
according to data compiled by LSEG.
(Reporting by Siddhi Mahatole in Bengaluru)